Here is a scenario that may be surprising: a person in great shape, athletic, with good LDL cholesterol levels, and yet they ...

Lipoprotein (a) is a cholesterol that carries lipoprotein – particles made of fats and proteins – in your blood. It’s structurally similar to LDL (low-density lipoprotein, or “bad” cholesterol), but ...

Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...

Michael D. Shapiro, DO, discusses how lipoproteins, chiefly LDL (low-density lipoprotein) and Lp(a) (lipoprotein a), drive atherosclerotic heart disease. This is a video synopsis/summary of an ...

The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Treatment with zerlasiran produced sustained reductions in lipoprotein(a) [Lp(a)] concentrations out to 1 year in adults with elevated Lp(a), extended data from the APOLLO phase 1 trial showed.